OM
AVIR icon

Opaleye Management’s Atea Pharmaceuticals AVIR Stock Holding History

Opaleye Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Sell
235,000
-87,600
-27% -$436K 0.1% 53
2026
Q1 		$1.74M Buy
322,600
+142,785
+79% +$656K 0.23% 45
2025
Q4 		$642K Buy
+179,815
New +$571K 0.08% 51

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Opaleye Management's AVIR Position: Q2 2026 in Review

Opaleye Management reduced its Atea Pharmaceuticals (AVIR) stake by 27% in Q2 2026, selling an estimated $436K and leaving 235,000 shares worth $1.09M. The position accounts for 0.1% of the portfolio, ranked #53.

Opaleye Management first reported a position in AVIR in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.74M in Q1 2026. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Opaleye Management held 235,000 shares of Atea Pharmaceuticals worth $1.09M as of Q2 2026.
  • Opaleye Management sold 87,600 Atea Pharmaceuticals shares in Q2 2026, an estimated $436K.
  • Atea Pharmaceuticals made up 0.1% of Opaleye Management's portfolio in Q2 2026, its #53 holding.
  • Opaleye Management first reported a position in Atea Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Opaleye Management's Atea Pharmaceuticals position peaked at $1.74M in Q1 2026.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.